Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.2K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Metastasis02:30

Metastasis

6.0K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.0K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

2.5K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PRECISE European initiative for cancer-vulnerability mapping and prediction.

Nature genetics·2026
Same author

Evolving patterns of co-mutations from tumor initiation to metastatic progression.

Nature genetics·2026
Same author

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026
Same author

SMPD3 suppresses oligodendroglioma growth via dual autocrine-paracrine roles.

Communications biology·2026
Same author

Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.

Translational gastroenterology and hepatology·2026
Same author

Cathepsin S regulates germinal center reactions and anti-tumor humoral responses.

The Journal of experimental medicine·2026

Related Experiment Video

Updated: Nov 7, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.

Sadegh Saghafinia1,2,3, Krisztian Homicsko1, Annunziata Di Domenico4

  • 1Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.

Cancer Discovery
|April 29, 2021
PubMed
Summary

Aggressive pancreatic neuroendocrine tumors (PanNET) develop from less aggressive islet tumors (IT) through dedifferentiation. This transition, driven by miR-181cd, precedes tumor cell proliferation and is linked to poorer patient outcomes.

More Related Videos

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.4K
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.5K

Related Experiment Videos

Last Updated: Nov 7, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.4K
Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Developmental Biology

Background:

  • Pancreatic neuroendocrine tumors (PanNET) present distinct molecular subtypes: benign islet tumors (IT) and aggressive metastasis-like primary (MLP) tumors.
  • The origin and progression pathway of aggressive MLP tumors from IT have remained largely unknown.

Purpose of the Study:

  • To elucidate the molecular mechanisms driving the transition from IT to MLP tumors.
  • To identify key regulators and temporal dynamics of PanNET tumorigenesis.

Main Methods:

  • Multi-omics approaches were employed to analyze tumor molecular phenotypes.
  • Investigated the role of the miR-181cd cluster and transcription factors Meis2 and Hmgb3 in tumor progression.

Main Results:

  • MLP tumors arise from IT via dedifferentiation, reversing the developmental pathway of islet β cells and adopting a progenitor-like phenotype.
  • The miR-181cd cluster promotes this transition by downregulating Meis2, leading to increased Hmgb3 expression.
  • This dedifferentiation step is temporally distinct and precedes accelerated tumor cell proliferation.

Conclusions:

  • Dedifferentiation is a separable, early step in PanNET tumorigenesis, preceding proliferation.
  • Elevated HMGB3 and an MLP signature correlate with higher tumor grade and worse patient survival.
  • This study reveals a novel mechanism of cancer cell plasticity enabling malignant progression in PanNET.